OP \$65.00 4214414

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 ETAS ID: TM368726 Stylesheet Version v1.2

SUBMISSION TYPE:NEW ASSIGNMENTNATURE OF CONVEYANCE:NUNC PRO TUNC ASSIGNMENTEFFECTIVE DATE:12/29/2015

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Maxim Pharmaceuticals, Inc.		01/06/2016	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Immune Pharmaceuticals, Inc.	
Street Address:	430 East 29th Street, Suite 940	
City:	New York	
State/Country:	NEW YORK	
Postal Code:	10016	
Entity Type:	CORPORATION: DELAWARE	

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Registration Number:	4214414	CEPLENE
Registration Number:	2967403	CEPLENE

CORRESPONDENCE DATA

Fax Number: 9497609502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (949) 760-0404

Email: efiling@knobbe.com

Correspondent Name: Lori L. Yamato

Address Line 1: 2040 Main Street, 14th Floor Address Line 4: Irvine, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	MAXIM.157T/221T	
NAME OF SUBMITTER:	Charlene A. Azema, Member CA bar	
SIGNATURE:	/charlene a. azema/	
DATE SIGNED:	01/11/2016	

Total Attachments: 2

source=Confirmation of Trademark Assignment - U.S. Trademarks#page1.tif source=Confirmation of Trademark Assignment - U.S. Trademarks#page2.tif

TRADEMARK REEL: 005706 FRAME: 0626

Confirmation of Trademark Assignment

This Confirmation of Trademark Assignment, effective as of December 29, 2015, is by and between MAXIM PHARMACEUTICALS, INC., a Delaware corporation ("ASSIGNOR"), and IMMUNE PHARMACEUTICALS, INC., a Delaware corporation ("ASSIGNEE").

ASSIGNOR hereby confirms that, for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, as of the Effective Date set forth above, it has assigned and transferred, and hereby assigns and transfers to the extent that it has not already done so, to ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in, to, and under (i) the trademarks, trademark applications and registrations listed on Schedule 1, attached hereto and hereby incorporated by this reference (collectively, "Registrations"); (ii) all other rights appurtenant to the Registrations, including without limitation, the goodwill associated with or symbolized by the marks, all common law rights, trade name rights, causes of action and the right to recover for past infringement ("Related Rights"); and (iii) certain tangible assets as indicia of the goodwill in the Registrations and Related Rights.

IN WITNESS WHEREOF, the parties have caused this instrument to be executed, effective as of the day and year first above written.

MAXIM PHARMACEUTICALS, INC.	IMMUNE PHARMACEUTICALS, INC.
Ву:	By:
Name: <u>Dr. Daniel Teper</u>	Name: Dr. Daniel Teper
Title: CEO	Title: CEO
Date: 1/6/2016	Date: 1/6/20/6


TRADEMARK REEL: 005706 FRAME: 0627

Schedule 1

US Matters

Trademarks Applications

Application No.	Patent No.
85/307577	
86/437617	
75/045348	2095894
75/146908	
75/146909	2182777
76/138210	
76/138211	3252103
76/138212	2967403
85/009435	
85/021009	4214414



RECORDED: 01/11/2016

TRADEMARK REEL: 005706 FRAME: 0628